Michael Shalmi

Managing Director, Principal Investments at Novo Holding A/S

Michael Shalmi

Michael Shalmi

Managing Director, Principal Investments at Novo Holding A/S

Overview
RelSci Relationships

313

Number of Boards

6

Birthday

1965

Age

53

Relationships
RelSci Relationships are individuals Michael Shalmi likely has professional access to. A relationship does not necessarily indicate a personal connection.

Advisor at VF Venture

Relationship likelihood: Strong

Executive Chairman at Orexo AB

Relationship likelihood: Strong

Chief Executive Officer & Director at Momentum Gruppen A/S

Relationship likelihood: Strong

Co-Founder at Aerocrine AB

Relationship likelihood: Strong

Former Chief Financial Officer at Novo Holding A/S

Relationship likelihood: Strong

Founding Partner at HealthCap AB

Relationship likelihood: Strong

Senior Principal at Cinven Group Ltd.

Relationship likelihood: Strong

Group Chief Executive Officer at Synlab International GmbH

Relationship likelihood: Strong

Partner at Cinven Group Ltd.

Relationship likelihood: Strong

Partner at Cinven Group Ltd.

Relationship likelihood: Strong

Paths to Michael Shalmi
Potential Connections via
Relationship Science
You
Michael Shalmi
Managing Director, Principal Investments at Novo Holding A/S
Education

With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark. The purpose of the University – to quote the University Statute – is to ’conduct research and provide further education to the highest academic level’.

Watching SIMI - Scandinavian International Management Institute.

Career History
Managing Director
2009 - Current

Novo Large Investments is an active, long-term manager which invests in successful later-stage private and publicly listed life science companies (with a bias towards late-clinical and early commercial stage product-focused companies). Their geographic focus is on companies in Denmark, Europe and North America.The firm acts as venture catalysts, investing later in the life cycle of promising life science companies, aiming to catalyze their value by providing ongoing support in the form of constructive advice and access to their network, insight and capabilities until tangible results materialize.Novo Large Investments typically invests USD 20-50 million in companies based on unique science which promote compelling, commercially relevant products and which are driven by insightful leadership, and have the ability to go substantially higher when required. They prefer to take significant minority stakes in their investee companies.

Managing Director, Principal Investments
Current

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation’s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Chief Medical Officer, BioPharm
2008 - 2009

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Boards & Committees
Member-Supervisory Board
2017 - Current

Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the EVT Execute and EVT Innovate segments. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include research fees, milestones and royalties. The EVT Innovate segment focuses on building a longterm partnered pharmaceutical pipeline from its own, internally developed assets and platforms. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Director
2017 - Current

SYNLAB Ltd. provides clinical laboratory services. It offers drug testing, food testing, hospital partnerships, specialist services, and veterinary. The company was founded on June 9, 2015 and is headquartered in London, the United Kingdom.

Director
2014 - Current

Aerocrine AB engages in the sale of medical technology products that are used to facilitate the diagnosis and improve the treatment and monitoring of patients with airway inflammation. It offers NIOX Flex and NIOX MINO, which are tools to assist in the diagnosis and control of airways disease. The company operates through the North America or USA and EU or the Rest of the World segments. Aerocrine was founded by Lars Gustafsson, Jon Lundberg and Eddie Weitzberg in November 1997 and is headquartered in Solna, Sweden.